Vera Therapeutics Inc
VERA
Company Profile
Business description
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.
Contact
8000 Marina Boulevard
Suite 120
BrisbaneCA94005
USAT: +1 650 770-0077
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
224
Stocks News & Analysis
stocks
After slump this ASX share may be an opportunity
Lower than expected guidance led to a sell-off.
stocks
Investment decisions in overvalued bank drive strong results
Shares fall despite a broadly unchanged outlook.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,111.60 | 40.60 | -0.44% |
| CAC 40 | 8,055.51 | 105.33 | 1.32% |
| DAX 40 | 23,959.99 | 390.03 | 1.65% |
| Dow JONES (US) | 47,368.63 | 381.53 | 0.81% |
| FTSE 100 | 9,787.15 | 104.58 | 1.08% |
| HKSE | 26,715.26 | 66.20 | 0.25% |
| NASDAQ | 23,527.17 | 522.64 | 2.27% |
| Nikkei 225 | 51,229.51 | 317.75 | 0.62% |
| NZX 50 Index | 13,544.64 | 72.84 | -0.53% |
| S&P 500 | 6,832.43 | 103.63 | 1.54% |
| S&P/ASX 200 | 8,832.00 | 43.60 | -0.49% |
| SSE Composite Index | 4,012.60 | 6.00 | -0.15% |